阿爾茨海默氏症：競爭的療法與市場動態 是由出版商BioPharm Reports (Technology and Markets Ltd)在2010年06月所出版的。
這份英文市場調查報告書包含114 Pages 價格從美金2397起跳。
目前有500萬的美國人患有阿爾茨海默氏症，若持續找不出有效的治療方法，預估在2050年病患數將會激增至1,400萬人。
本報告書針對阿爾茨海默氏症目前的治療動態進行調查，依據該症狀的嚴重程度，彙整了個別的處方與藥劑等級等未來課題介紹，內容概要摘記如下。
第1章 背景
第2章 調查
第3章 參加者
第4章 阿爾茨海默氏症患者
第5章 輕度阿爾茨海默氏症的處方藥劑級別
第6章 輕度阿爾茨海默氏症所使用的合併藥劑
第7章 中度阿爾茨海默氏症的處方藥劑級別
第8章 中度阿爾茨海默氏症所使用的合併藥劑
第9章 重度阿爾茨海默氏症的處方藥劑級別
第10章 重度阿爾茨海默氏症所使用的合併藥劑
第11章 調查對象
第12章 議論
附錄
圖表
Abstract
This report presents the findings of a clinical survey of
current treatment practices for Alzheimer' s Disease (AD). This was carried out
following the participation of more than 220 physicians, practicing
predominantly in the US. The purpose of this study was to establish current
drug treatment practices for AD and how current drug classes, individually and
in combination, are prescribed for mild, moderate and severe stages of the
disease. As part of this survey, physicians reported on the principal
challenges of treating this disease and these findings are presented, analysed
and discussed in this report. This survey was also carried out to evaluate
market entry factors, relating to the treatment of AD.
The treatment of AD remains an area of significant unmet need, with therapies
based largely on two drug classes: the cholinesterase inhibitors and the NMDA
receptor antagonists. These drugs target the symptoms of the disease, however
there is considerable need for disease-modifying therapies. Other therapeutic
agents are used to treat this disease, which have also been surveyed as part
of this work. This survey investigated the use of these drug classes for the
treatment of mild, moderate and severe AD, as well as examining the use of
drug combinations. While available drugs to treat AD are limited, current
practices in how they are used and combined in treating mild, moderate and
severe disease, vary greatly. This survey has examined current treatment
practices, which includes off-label use.
In a therapeutic field where treatments for AD are very limited, physicians
seek to extent their understanding in this area in an effort to better
understand how current drugs and combinations can best be used to target mild,
moderate and severe stages. Knowledge in these areas is also important to drug
developers, who seek a better understanding of patient needs and outcomes as
part of their own efforts to develop more effective therapies. The present
survey was carried out to meet interest in these areas.
This report presents an analysis of the survey findings and includes:
- 1) Clinics: comprehensive details of current treatments for AD,
provided by more than 220 clinics.
- 2) Markets and opportunities: in-depth information and analysis
relevant to therapeutic markets and opportunities in the AD field.
- 3) Physicians: of the participants, 92% practiced in the US, 2%
practiced in Canada and 6% in other countries. Of these, 28% worked in a
geriatric department, 20% practiced in a hospital general department, 15%
worked in a general practice and 10% worked in a university research/clinical
practice. Approximately 90% of the participants worked as Geriatricians and 5%
were General Physicians.
- 4) Disease stages: estimates of the percentage (%) of AD patients
treated by study participants for mild, moderate or severe disease.
- 5) Mild AD: estimates of the percentage (%) of mild AD patients who
are prescribed Cholinesterase Inhibitors (e.g. donepezil, Aricept®
rivastigmine, Exelon® galantamine, Reminyl® NMDA Receptor Antagonist (e.g.
memantine - Namenda®, Axura®, Ebixa® Nootropics (e.g. piracetam -
Nootropil®); and other drug classes.
- 6) Mild AD: first choice and second choice drug combinations of two
or more of the drug classes Cholinesterase Inhibitors; NMDA Receptor
Antagonist; Nootropics; Colostrinin; Vitamins and other drugs for the
treatment of mild disease.
- 7) Moderate AD: estimates of the percentage (%) of moderate
Alzheimer' s disease patients who are prescribed Cholinesterase Inhibitors
(e.g. donepezil, Aricept® rivastigmine, Exelon® galantamine, Reminyl® NMDA
Receptor Antagonist (e.g. memantine - Namenda®, Axura®, Ebixa® Nootropics
(e.g. piracetam - Nootropil®); and other drug classes.
- 8) Moderate AD: first and second-choice drug combinations of two or
more of the drug classes Cholinesterase Inhibitors; NMDA Receptor Antagonist;
Nootropics; Colostrinin; Vitamins and other drugs for the treatment of
moderate disease.
- 9) Severe AD: estimates of the percentage (%) of severe AD patients
who are prescribed Cholinesterase Inhibitors (e.g. donepezil, Aricept®
rivastigmine, Exelon® galantamine, Reminyl® NMDA Receptor Antagonist (e.g.
memantine - Namenda®, Axura®, Ebixa® Nootropics (e.g. piracetam -
Nootropil®); and other drug classes.
- 10) Severe AD: first and second-choice drug combinations of two or
more of the drug classes Cholinesterase Inhibitors; NMDA Receptor Antagonist;
Nootropics; Colostrinin; Vitamins and other drugs for the treatment of severe
disease.
- 11) The principal challenges and issues encountered in the
treatment of Alzheimer' s disease.
Background to Alzheimer' s disease
A prevalence study in 2005 estimated there were 24.3 million people suffering
from dementia globally, with 4.6 million new cases added every year. In the
absence of a cure, the study suggested dementia sufferers will double every 20
years to 81.1 million by 2040. Of those reported to be suffering from
dementia, 60% were living in developing countries, a figure expected to rise
to 70% by 2040. Rates of increase of dementia are not uniform, and between
2001 and 2040 were projected to increase by 100% in developed countries and by
more than 300% in India, China, and their south Asian and western Pacific
neighbours. More than 50% of these dementia cases are due to AD.
Today, approximately five million Americans suffer from AD, a figure expected
to rise to 14 million by 2050 if a cure is not found. One in eight persons in
the US over the age of 65 and nearly half of those over 85 have AD. Direct and
indirect costs of AD and other dementias in the US amount to more than $148
billion annually. It is estimated that 10 million Americans are caring for a
person with AD or another dementia, one third of whom are over the age of 60.
It is estimated the worldwide costs for dementia care are over $315 billion
annually.
Report Statistics
- Format: PDF
- Number of pages: 114
Table of Contents
Executive Summary
Chapter 1 - Background
- 1. Alzheimer' s disease
- 1.1 Statistics and costs
- 1.2 Treatment
- 1.3 This report
Chapter 2 - The Survey
- 2.1 The survey
- 2.2 Survey questions
Chapter 3 - Survey Participants
- 3.1 Summary
- 3.2 Overview
- 3.3 Findings
Chapter 4 - Alzheimer' s Disease Patients
- 4.1 Summary
- 4.2 Overview
- 4.3 Findings
Chapter 5 - Drug Classes Prescribed For Mild Alzheimer' s Disease
- 5.2 Overview
- 5.3 Findings
Chapter 6 - Drug Combinations used in Mild Alzheimer' s Disease
- 6.1 Summary
- 6.2 Overview
- 6.3 Findings
Chapter 7 - Drug Classes Prescribed for Moderate Alzheimer' s Disease
- 7.1 Summary
- 7.2 Overview
- 7.3 Findings
Chapter 8 - Drug Combinations used in Mild Alzheimer' s Disease
- 8.1 Summary
- 8.2 Overview
- 8.3 Findings
Chapter 9 - Drug Classes Prescribed for Severe Alzheimer' s Disease
- 9.1 Summary
- 9.2 Overview
- 9.3 Findings
Chapter 10 - Drug Combinations used in Severe Alzheimer' s Disease
- 10.1 Summary
- 10.2 Overview
- 10.3 Findings
Chapter 11 - Study Participants
Chapter 12 - Discussion
- 12.1 Treatment practices
- 12.2 Challenges and issues
- 12.3 Oppor
Appendix - 1
Figures
- Figure 3.1 Participant countries
- Figure 3.2 Participant organisations
- Figure 3.4 Participant physicians
- Figure 4.1 Percentage of patients with mild Alzheimer' s disease
- Figure 4.2 Percentage of patients with moderate Alzheimer' s disease
- Figure 4.3 Percentage of patients with severe Alzheimer' s disease
- Figure 4.4 Mean Percentage of patients with mild, moderate or severe
Alzheimer' s disease
- Figure 5.1 Percentage of mild Alzheimer' s disease patients prescribed a
cholinesterase inhibitors
- Figure 5.2 Percentage of mild Alzheimer' s disease patients prescribed an
NMDA receptor antagonist
- Figure 5.3 Percentage of mild Alzheimer' s disease patients prescribed a
nootropic
- Figure 5.4 Percentage of mild Alzheimer' s disease patients prescribed
other drugs
- Figure 5.5 Percentage of mild Alzheimer' s disease patients prescribed all
drugs
- Figure 6.1 First choice drug combinations used in the treatment of mild
Alzheimer' s disease
- Figure 6.2 Second choice drug combinations used in the treatment of mild
Alzheimer' s disease
- Figure 7.1 Percentage of moderate Alzheimer' s disease patients prescribed
a cholinesterase inhibitors
- Figure 7.2 Percentage of moderate Alzheimer' s disease patients prescribed
an NMDA receptor antagonist.
- Figure 7.3 Percentage of moderate Alzheimer' s disease patients prescribed
a nootropic.
- Figure 7.4 Percentage of moderate Alzheimer' s disease patients prescribed
other drugs.
- Figure 7.5 Percentage of moderate Alzheimer' s disease patients prescribed
all drugs
- Figure 8.1 First choice drug combinations used in the treatment of
moderate Alzheimer' s disease
- Figure 8.2 Second choice drug combinations used in the treatment of mild
Alzheimer' s disease
- Figure 9.1 Percentage of severe Alzheimer' s disease patients prescribed a
cholinesterase inhibitors
- Figure 9.2 Percentage of severe Alzheimer' s disease patients prescribed an
NMDA receptor antagonist.
- Figure 9.3 Percentage of severe Alzheimer' s disease patients prescribed a
nootropic.
- Figure 9.4 Percentage of severe Alzheimer' s disease patients prescribed
other drugs.
- Figure 9.5 Percentage of severe Alzheimer' s disease patients prescribed
all drugs
- Figure 10.1 First choice drug combinations used in the treatment of severe
Alzheimer' s disease
- Figure 10.2 Second choice drug combinations used in the treatment of
severe Alzheimer' s disease
- Figure 12.1 Percentage of mild Alzheimer' s disease patients prescribed
cholinesterase inhibitors
- Figure 12.4 Top-10 limitations and issues encountered in the treatment of
Alzheimer' s disease
Tables
- Table 3.1 Participant organisations
- Table 5.1 Other treatments used for patients with mild Alzheimer' s disease
- Table 6.1 First choice drug combinations used in the treatment of mild
Alzheimer' s disease
- Table 6.2 Second choice drug combinations used in the treatment of mild
Alzheimer' s disease
- Table 7.1 Other treatments used for patients with moderate Alzheimer' s
disease
- Table 8.1 First choice drug combinations used in the treatment of moderate
Alzheimer' s disease
- Table 8.2 Second choice drug combinations used in the treatment of
moderate Alzheimer' s disease
- Table 9.1 Other treatments used for patients with moderate Alzheimer' s
disease
- Table 10.1 First choice drug combinations used in the treatment of severe
Alzheimer' s disease
- Table 10.3 Second choice drug combinations used in the treatment of severe
Alzheimer' s disease
- Table 11.1 Study Participants
- Table 12.1 The percentage of mild, moderate and severe AD patients who are
prescribed cholinesterase inhibitors, NMDA receptor antagonists, nootropics
and other drugs
- Table 12.2 The percentage of physicians prescribing cholinesterase
inhibitors and NMDA receptor antagonists to 50% or less of their mild,
moderate or severe Alzheimer' s disease patients.
- Table 12.3 First and second choice prescribing patterns for mild, moderate
or severe Alzheimer' s disease using either cholinesterase inhibitors of NMDA
receptor antagonists, independently of other drugs.
- Table 12.4 Limitations and issues encountered in the treatment of
Alzheimer' s disease
Appendix 1.
Responses provided by study participants to the question:
What are the major issues and challenges associated with the treatment of
Alzheimer' s disease? Responses given by physicians to this question (which in
some cases may be brief, informal or abbreviated) are presented verbatim,
except in those some cases where minor grammatical or typographical
corrections have been made for reasons of clarity.
|
